Apremilast reduces the number of oral ulcers in Behçet’s syndrome, results of a phase II trial show. The randomized placebo-controlled trial involved 111 patients in Turkey and the United States who were treated for 12-24 weeks. The average number of oral ulcers at week 12 was significantly lower in the apremilast group (0.5) than in the ...
Apremilast heals oral ulcers in Behçets
20 Apr 2015